ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Abstract Number: 0229

The Effects of Self-efficacy on Fatigue and Pain Interference in Black Women with Systemic Lupus Erythematosus: The Role of Depression, Age, and Education

Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

8:30AM-10:30AM: Abstract Number: 0121

The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression

Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)

8:30AM-10:30AM: Abstract Number: 0296

The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0232

The Impact of Deucravacitinib on Health-Related Quality of Life Measured by the Short Form Health Survey 36-Item Questionnaire: Analysis of a Phase 2 Trial in Patients with Active PsA

Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

8:30AM-10:30AM: Abstract Number: 0238

The Impact of Preeclampsia on Pregnancies and Infants of Women with Rheumatic Disease

Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

8:30AM-10:30AM: Abstract Number: 0336

The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0158

The Influence of Age on the Prevalence of Inflammatory and Post-inflammatory MRI Lesions in the Sacroiliac Joints of Patients with and Without Axial Spondyloarthritis

Imaging of Rheumatic Diseases Poster (0149–0182)

8:30AM-10:30AM: Abstract Number: 0025

The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0036

The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0348

The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0217

The OMERACT Knee Inflammation MRI Scoring System: Validation of Quantitative Methodologies and Tri-compartmental Overlays by Comparison with the MRI Osteoarthritis Knee Score

Osteoarthritis – Clinical Poster I (0210–0224)

8:30AM-10:30AM: Abstract Number: 0377

The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)

8:30AM-10:30AM: Abstract Number: 0266

The Psychosocial Impact of the COVID-19 Pandemic on the Rheumatology Patient Experience

Psychology/Social Sciences Poster (0266–0267)

8:30AM-10:30AM: Abstract Number: 0356

The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0114

The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.